JP2009523140A5 - - Google Patents

Download PDF

Info

Publication number
JP2009523140A5
JP2009523140A5 JP2008549781A JP2008549781A JP2009523140A5 JP 2009523140 A5 JP2009523140 A5 JP 2009523140A5 JP 2008549781 A JP2008549781 A JP 2008549781A JP 2008549781 A JP2008549781 A JP 2008549781A JP 2009523140 A5 JP2009523140 A5 JP 2009523140A5
Authority
JP
Japan
Prior art keywords
alkoxy
alkyl
aryl
halogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008549781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009523140A (ja
Filing date
Publication date
Priority claimed from FR0600347A external-priority patent/FR2896161B1/fr
Application filed filed Critical
Publication of JP2009523140A publication Critical patent/JP2009523140A/ja
Publication of JP2009523140A5 publication Critical patent/JP2009523140A5/ja
Pending legal-status Critical Current

Links

JP2008549781A 2006-01-13 2006-12-18 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用 Pending JP2009523140A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600347A FR2896161B1 (fr) 2006-01-13 2006-01-13 Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
PCT/EP2006/012183 WO2007079915A2 (en) 2006-01-13 2006-12-18 Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect

Publications (2)

Publication Number Publication Date
JP2009523140A JP2009523140A (ja) 2009-06-18
JP2009523140A5 true JP2009523140A5 (enExample) 2010-02-12

Family

ID=36658622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549781A Pending JP2009523140A (ja) 2006-01-13 2006-12-18 瘢痕形成または血管形成効果を有する医薬の製造のためのトリアジン誘導体の使用

Country Status (22)

Country Link
US (1) US8217040B2 (enExample)
EP (1) EP1971329B1 (enExample)
JP (1) JP2009523140A (enExample)
KR (1) KR101482686B1 (enExample)
CN (1) CN101355931A (enExample)
AR (1) AR059034A1 (enExample)
AU (1) AU2006334732B2 (enExample)
BR (1) BRPI0620983B8 (enExample)
CA (1) CA2636838C (enExample)
CY (1) CY1119872T1 (enExample)
DK (1) DK1971329T3 (enExample)
EA (1) EA016127B1 (enExample)
ES (1) ES2647912T3 (enExample)
FR (1) FR2896161B1 (enExample)
HU (1) HUE037217T2 (enExample)
IL (1) IL192595A (enExample)
LT (1) LT1971329T (enExample)
PL (1) PL1971329T3 (enExample)
PT (1) PT1971329T (enExample)
SI (1) SI1971329T1 (enExample)
WO (1) WO2007079915A2 (enExample)
ZA (1) ZA200806946B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP2020536121A (ja) 2017-10-02 2020-12-10 ポクセルPoxel 駆出率が保持された心不全を治療する方法
CA3102412A1 (en) 2018-06-06 2019-12-12 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
WO2019238647A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
EP4014962A1 (de) * 2020-12-16 2022-06-22 Novigo GmbH & Co. KG Zusammensetzung mit osmotisch wirksamer substanz und verwendung der zusammensetzung
FR3149774B1 (fr) * 2024-01-11 2025-06-20 Fabre Pierre Dermo Cosmetique 5,6,5’,6’-tétraphényl-3,3’-(1,4-phénylène)-bis[1,2,4]triazine pour améliorer l’aspect des cicatrices et/ou réduire les marques cicatricielles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150362A (en) * 1997-12-12 2000-11-21 Henkin; Jack Triazine angiogenesis inhibitors
DK1037886T3 (da) * 1997-12-12 2003-08-25 Abbott Lab Triazin angiogeneseinhibitorer
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
AU2003289375A1 (en) * 2002-12-17 2004-07-09 Hamari Chemicals, Ltd Novel 2,4-diamino-1,3,5-triazine derivative
FR2853650B1 (fr) * 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance

Similar Documents

Publication Publication Date Title
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
JP2019094345A5 (enExample)
JP2018511647A5 (enExample)
JP2017531020A5 (enExample)
RU2009102535A (ru) Производные карбамидов тропана, их получение и их применение в терапии
PH12012501773A1 (en) Arylethynyl derivatives
JP2004516314A5 (enExample)
AR064304A1 (es) Formulaciones de ansamicina y sus metodos de uso
JP2015537020A5 (enExample)
JP2016527277A5 (enExample)
JP2009504764A5 (enExample)
JP2014503525A5 (enExample)
JP2006515858A5 (enExample)
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
JP2016506959A5 (enExample)
JP2013500304A5 (enExample)
JP2009523139A5 (enExample)
JP2015535847A5 (enExample)
CR20200584A (es) Compuestos tetrahidro-1h-pirazino [2,1-a] isoindolilquinolina para el tratamiento de enfermedades autoinmunes
IL276711B1 (en) Arginase inhibitors and methods of use thereof
JP2019535723A5 (enExample)
JP2009523142A5 (enExample)
JP2016529235A5 (enExample)
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet